Guru Fundamental Report for EMR

Validea's guru fundamental report indicates Emerson Electric (EMR) received a 75% rating from its Multi-Factor Investor model, based on Pim van Vliet's low-volatility, momentum, and high net payout yield strategy. This score falls below the 80% threshold for 'some interest' by the model, primarily due to neutral momentum and net payout yield metrics, culminating in an overall 'FAIL' for its final rank despite passing market cap and standard deviation criteria. The assessment suggests EMR is not a strong fit for this specific conservative, factor-based investment approach.

Analysis

According to a Validea fundamental report, Emerson Electric (EMR) does not align with the criteria of the Pim van Vliet-based Multi-Factor Investor model, which prioritizes a combination of low volatility, strong momentum, and high net payout yield. The stock achieved a score of 75%, falling short of the 80% threshold that indicates model interest and culminating in a 'FAIL' on its final rank. While EMR successfully passed the model's screens for large market capitalization and low volatility (standard deviation), its performance was lacking in two key areas. The company received 'NEUTRAL' ratings for both 'Twelve Minus One Momentum' and 'Net Payout Yield', suggesting that while it possesses the desired low-risk characteristics, it currently lacks the strong recent price performance and robust shareholder return profile sought by this specific conservative factor strategy. The resulting moderately negative sentiment score of -0.4 is a direct reflection of this quantitative model's specific disapproval, rather than a broader commentary on the company's intrinsic business health.

Key Decisions for Investors

• Investors who strictly follow conservative, factor-based strategies focusing on low-volatility, high-momentum, and high-yield should consider this 'FAIL' rating a signal to avoid or underweight EMR.
• For investors with a different thesis, such as long-term growth or fundamental value, this report's findings may be less critical, but the neutral readings on momentum and net payout yield warrant a closer look at EMR's recent performance and capital allocation policies.
• Current holders of EMR should recognize that the stock's low-volatility profile may add a defensive quality to a portfolio, but its weak momentum and yield factors could lead to underperformance relative to peers if those factors are driving market returns.